Compugen Ltd. (NASDAQ:CGEN) shares rose 3.8% on Thursday . The company traded as high as $6.94 and last traded at $6.91, with a volume of 66,127 shares changing hands. The stock had previously closed at $6.66.

CGEN has been the topic of a number of recent analyst reports. FBR & Co reissued a “buy” rating on shares of Compugen in a research note on Thursday, May 12th. Zacks Investment Research lowered Compugen from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.25.

The firm has a 50 day moving average of $6.70 and a 200 day moving average of $6.24. The stock’s market cap is $355.85 million.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. On average, equities research analysts expect that Compugen Ltd. will post ($0.56) earnings per share for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.